Inte 121 Application No PC | / BE 2004 / 000118

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61P07/02 A61K A61K39/395 C07K16/36 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, Sequence Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Category ° Relevant to claim No. X WO 01/04269 A (SAINT REMY JEAN MARIE R ; 30,31 JACQUEMIN MARC G (BE); LEUVEN RES & DEV VZW) 18 January 2001 (2001-01-18) page 25, line 4 - page 26, line 8 examples 5,7 figures 8,9 X KALLAS ADE ET AL: "Epitope specificity of 26,30,31 anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor." THROMBOSIS RESEARCH. vol. 107, no. 6, 15 September 2002 (2002-09-15), pages 291-302, XP008041463 ISSN: 0049-3848 page 295, right-hand column, paragraph 2 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the International "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled O' document referring to an oral disclosure, use, exhibition or other means \*P\* document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 19 January 2005 02/02/2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 COVONE-VAN HEES. M

Inter nal Application No PCT/BE2004/000118

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	FC1/BE2004/000118	
Category °		Relevant to claim No.	
X	SINGH INDERJIT ET AL: "Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model."  BLOOD. 1 MAY 2002, vol. 99, no. 9, 1 May 2002 (2002-05-01), pages 3235-3240, XP002314128 ISSN: 0006-4971	30,31	
Α	the whole document	15–19	
Α	WRIGHT A: "ANTIBODY VARIABLE REGION GLYCOSYLATION: POSITION EFFECTS ON ANTIGEN BINDING AND CARBOHYDRATE STRUCTURE" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 10, 1 October 1991 (1991-10-01), pages 2717-2723, XP000219694 ISSN: 0261-4189 page 2717, right-hand column, lines 25-31 page 2720, right-hand column, lines 1-6 page 2721, left-hand column, lines 14-17 table II	1-33	
A	KATO MASATOSHI ET AL: "Activity enhancement of a lung cancer-associated human monoclonal antibody HB4C5 by N-deglycosylation" HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 4, no. 1, 1993, pages 9-14, XP008041607 abstract	1-33	
A	SATO KOH ET AL: "Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region" HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 7, no. 4, 1996, pages 175-183, XP008041468 ISSN: 0956-960X abstract	1-33	
A	KHURANA SUMIT ET AL: "The variable domain glycosylation in a monoclonal antibody specific to GnRH modulates antigen binding" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 234, no. 2, 1997, pages 465-469, XP008041466 ISSN: 0006-291X page 467, left-hand column, paragraph 2	1-33	

Inte 1al Application No
PC | / pE2004/000118

C (O===1	Alexa DOGULERIES COMORDEDES TO DE DEL MANTE	FC1/BE2004/000118	
Category °	etion) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
	on another than made them, where appropriate, of the relevant passenges	TIBLE VALUE OF SEATING OF	
A	EP 0 822 255 A (WELLCOME FOUND) 4 February 1998 (1998-02-04) the whole document	1	
Ρ,Χ	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2003 (2003-11-16), JACQUEMIN MARC G ET AL: "Glycosylation of a type 2 factor VIII inhibitor determines its maximum level of FVIII inhibition." XP002314129 Database accession no. PREV200400181293	1-33	
Ρ,Χ	abstract & BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), page 163a, 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003 ISSN: 0006-4971	1-33	

tional application No. PCT/BE2004/000118

## **INTERNATIONAL SEARCH REPORT**

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 15-19 (partially) because they relate to subject matter hot required to be searched by this Authority, namely:
Although claims 15-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

rmation on patent family members

Inter and Application No PCT/BE2004/000118

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0104269	A	18-01-2001	AU	6273000 A	30-01-2001
			CA	2381125 A1	18-01-2001
			WO	0104269 A1	18-01-2001
			EP	1194528 A1	10-04-2002
			JP	2003504045 T	04-02-2003
EP 0822255	A	04-02-1998	EP	1247865 A2	09-10-2002
			EP	0822255 A2	04-02-1998
			ΑT	176926 T	15-03-1999
			ΑU	645355 B2	13-01-1994
			ΑU	8591491 A	30-04-1992
			CA	2053585 A1	18-04-1992
			DE	69130912 D1	01-04-1999
			DE	69130912 T2	02-09-1999
			DK	481790 T3	27-09-1999
			EP	1484402 A2	08-12-2004
			ΕP	0481790 A2	22-04-1992
			ES	2131507 T3	01-08-1999
			GR	3030289 T3	30-09-1999
			ΙE	913558 A1	22-04-1992
			JP	6090752 A	05-04-1994
			NZ	240249 A	25-03-1994
			US	2002182208 A1	05-12-2002
			US	2003035799 A1	20-02-2003
			US	5545403 A	13-08-1996
			US	5545404 A	13-08-1996
			US	5545405 A	13-08-1996
			US	2004228857 A1	18-11-2004
			ZA	9108248 A	16-04-1993